CHANG Jian,ZHANG Yu-Tong,ZHONG Xiao-Dan et al. Preliminary study on the efficacy of irinotecan in the treat,emt of childhood relapsed hepatoblastoma[J]. CJCP, 2013, 15(7): 588-590.
［1］Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continous infuson doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children′s Cancer Group and Pediatric Oncology Group［J］. J Clin Oncol, 2000,18(14): 2665-2675.
［2］Vassal G, Doz F, Frappaz D,Imadalou K, Sicard E, Santos A, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors［J］. J Clin Oncol, 2003, 21(20): 3844-3852.
［3］Bomgaars LR, Kerr J, Berg S, Kuttesch J, Klenke R, Blaney SM. A phase I study of irinotecan administered on a weekly schedule in pediatric patients［J］. Pediatr Blood Cancer, 2006, 46(1): 50-55.
［4］Palmer RD, Williams DM. Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11) ［J］. Med Pediatr Oncol, 2003,41(1):78-80.
［5］Roebuck DJ, Aronson D, Clapuyt P, Czauderna P, de Ville de Goyet J, Gauthier F, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumors of childhood developed by the SIOPEL group［J］. Pediar Radiol, 2007, 37(2): 123-132.
［6］Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children′s Oncology Group Study［J］. J Clin Oncol, 2007, 25( 29): 4622-4627.
［7］Qayed M, Powell C, Moran ER, Haugen M, Katzenstein HM. Iriontecan as maintenance therapy in high-risk hepatoblastoma［J］. Pediatr Blood Cancer, 2010, 54(5):761-763.
［8］Stringer AM, Gibson RJ, Bowen JM, Logan RM, Ashton K, Yeoh AS, et al. Irinotecan-induced mucositis manifesting as diarrheea corresponds with an amended intestinal flora and mucin profile［J］. Int J Exp Pathol, 2009, 90(5): 489-499.
［9］Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria［J］. Jpn J Clin Oncol, 2003, 33(10): 533-537.
［10］NCI. Common Terminology Criteria for Adverse Events (CTCAE)［EB/OL］. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/About. html. Accessed May, 17, 2010.
［11］Perilongo G, Shafford E, Maibach R, Aronson D, Brugières L, Brock P, et al. Risk-adapted treatment for childhood hepatoblastoma.final report of the second study of the International Society of Pacdiatric Oncologu-SIOPEL2［J］. Eur J Cancer, 2004, 40(3): 411-421.
［14］Haeberle B, Schweinitz DV. Treatment of hepatoblastoma in the German cooperative pediatric liver tumor studies［J］. Front Bissci(Elite Ed), 2012, 4: 493-498.
［15］Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr,et al. Phase Ⅰtrial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children′s Oncology Group phase Ⅰconsortium study［J］. Pediatr Blood Cancer, 2010, 54(4): 534-545.
［16］Venkatramani R, Furman WL, Fuchs J, Warmann SW, Malogolowkin MH. Current and future management strategies for relapsed or progressive hepatoblastoma［J］. Paediatr Drugs, 2012, 14(4):221-232.
